To the full analysis
Viemed Healthcare stock: growth
VMDViemed Healthcare reported $270.28M in revenue for fiscal 2025, up 20.5% on the prior year, up 15.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
25%
per year from 2014 to 2025, per share 5.4%
Earnings (Annual rate)
4.2%
per year from 2014 to 2025, per share −12.2%
Free cash flow (Annual rate)
5.3%
per year from 2014 to 2025, per share −11.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2014 | |
|---|---|---|---|
| Revenue | 15.5% | 21.8% | 25.0% |
| Revenue per share | 15.4% | 1.0% | 5.4% |
| Earnings | −13.9% | 5.3% | 4.2% |
| Earnings per share | −15.1% | −13.5% | −12.2% |
| Free cash flow | −11.6% | 2.6% | 5.3% |
| Free cash flow per share | −11.6% | −14.9% | −11.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2014 | $23.29M | $9.45M | $6.74M |
| 2015 | $37.57M | $8.93M | $9.25M |
| 2016 | $31.36M | $1.23M | $4.74M |
| 2017 | $46.93M | $8.18M | $8.02M |
| 2018 | $64.46M | $9.51M | $16.25M |
| 2019 | $80.26M | $8.53M | $5.7M |
| 2020 | $131.31M | $31.53M | $22.07M |
| 2021 | $117.06M | $9.13M | $2.75M |
| 2022 | $138.83M | $6.22M | $4.85M |
| 2023 | $183.01M | $10.24M | $19.12M |
| 2024 | $224.26M | $11.27M | $1.32M |
| 2025 | $270.28M | $14.93M | $11.93M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.